Biogen Idec (NASDAQ:BIIB) and its partner AbbVie (NYSE:ABBV) reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the drug from capturing a nice chunk of the third line treatment space.

In this episode of market checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss the trial results, the sales potential for dac, ultimately what it these results mean for investors in both stocks.



David Williamson owns shares of AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.